Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 12Central Nervous System Neoplasms 11Brain Neoplasms 9Astrocytoma 8Glioma 6Oligodendroglioma 4Gliosarcoma 3Neoplasms 2Medulloblastoma 2Leukemia, Myeloid, Acute 2Spinal Cord Neoplasms 1Optic Nerve Glioma 1Neoplasms, Plasma Cell 1Neoplasm Recurrence, Local 1Multiple Myeloma 1Cognition Disorders 1

Interventions

Mental Status and Dementia Tests 1Lomustine 1DNA Methylation 1Cognitive Training 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Cognition Disorders × Lomustine × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡